Cirrhotic cardiomyopathy: A cardiologist's perspective

World Journal of Gastroenterology

Volumn 20, Issue 42, 2014, Pages 15492-15498

  Gassanov, Natig ^a   Caglayan, Evren ^b   Semmo, Nasser ^c   Massenkeil, Gero ^a   Er, Fikret ^a  

^a Klinik für Anästhesiologie Intensiv Notfall und Schmerzmedizin   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cardiomyopathy; Cirrhosis; Diastolic dysfunction; Hyperdynamic circulation; Pathogenesis

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR; CALCIUM; CARBON MONOXIDE; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOCANNABINOID; NITRIC OXIDE;

ARTICLE; CALCIUM SIGNALING; CARDIOMYOPATHY; CIRRHOTIC CARDIOMYOPATHY; CLINICAL FEATURE; DIASTOLIC DYSFUNCTION; DIURETIC THERAPY; HEART ELECTROPHYSIOLOGY; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGENESIS; SYSTOLIC DYSFUNCTION; ANIMAL; CARDIOMYOPATHIES; COMPLICATION; HEART CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE FUNCTION; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CARDIOMYOPATHIES; HEART CONDUCTION SYSTEM; HUMANS; LIVER CIRRHOSIS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VENTRICULAR FUNCTION;

EID: 84912076864     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i42.15492     Document Type: Article

References (62)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32: 1025-1033 [PMID: 13096569 DOI: 10.1172/JCI102813]
2. Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989; 151: 530-535 [PMID: 2690463]
3. Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007; 2: 15 [PMID: 17389039 DOI: 10.1186/1750-1172-2-15]
4. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: Pathogenic mechanisms. World J Gastroenterol 2006; 12: 837-842 [PMID: 16521209]
5. Gerbes AL, Remien J, Jüngst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1: 1409-1411 [PMID: 2872517 DOI: 10.1016/S0140-6736(86)91556-4]
6. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology 1990; 12: 481-485 [PMID: 2169452 DOI: 10.1002/hep.1840120306]
7. Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996; 110: 1191-1198 [PMID: 8613009 DOI: 10.1053/gast.1996.v110.pm8613009]
8. Ma Z, Zhang Y, Huet PM, Lee SS. Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy. J Hepatol 1999; 30: 485-491 [PMID: 10190733 DOI: 10.1016/S0168-8278(99)80109-3]
9. Jaue DN, Ma Z, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997; 25: 1361-1365 [PMID: 9185753 DOI: 10.1002/hep.510250610]
10. Meddings J. Sucrose-how sweet is it? J Pediatr Gastroenterol Nutr 1997; 24: 621-622 [PMID: 9161964 DOI: 10.1097/0000517 6-199705000-00025]
11. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol 1994; 267: G87-G93 [PMID: 8048535]
12. Kakimoto H, Imai Y, Kawata S, Inada M, Ito T, Matsuzawa Y. Altered lipid composition and differential changes in activities of membrane-bound enzymes of erythrocytes in hepatic cirrhosis. Metabolism 1995; 44: 825-832 [PMID: 7616839 DOI: 10.1016/0026-0495(95)90233-3]
13. Imai Y, Scoble JE, McIntyre N, Owen JS. Increased Na(+)-dependent D-glucose transport and altered lipid composition in renal cortical brush-border membrane vesicles from bile duct-ligated rats. J Lipid Res 1992; 33: 473-483 [PMID: 1527471]
14. Reichen J, Buters JT, Sojcic Z, Roos FJ. Abnormal lipid composition of microsomes from cirrhotic rat liver-does it contribute to decreased microsomal function? Experientia 1992; 48: 482-486 [PMID: 1601113 DOI: 10.1007/BF01928168]
15. Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D. Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology 1987; 7: 149-154 [PMID: 3542775 DOI: 10.1002/hep.1840070129]
16. Lebrec D. Beta-blockers and portal hypertension, hemodynamic effects and prevention of recurrent gastrointestinal bleeding. Hepatogastroenterology 1990; 37: 556-560 [PMID: 1981204]
17. Mills PR, Rae AP, Farah DA, Russell RI, Lorimer AR, Carter DC. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 1984; 25: 73-78 [PMID: 6360815 DOI: 10.1136/gut.25.1.73]
18. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 2001; 121: 1209-1218 [PMID: 11677214 DOI: 10.1053/gast.2001.28653]
19. Kim YM, Bombeck CA, Billiar TR. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 1999; 84: 253-256 [PMID: 10024298 DOI: 10.1161/01.RES.84.3.253]
20. García-Estañ J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) 2002; 102: 213-222 [PMID: 11834141 DOI: 10.1042/CS20010154]
21. Albornoz L, Motta A, Alvarez D, Estevez A, Bandi JC, McCormack L, Matera J, Bonofiglio C, Ciardullo M, De Santibañes E, Gimeno M, Gadan A. Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: Relationship with hemodynamic disturbances. J Hepatol 2001; 35: 452-456 [PMID: 11682028 DOI: 10.1016/S0168-8278(01)00168-4]
22. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000; 118: 937-944 [PMID: 10784593 DOI: 10.1016/S0016-5085(00)70180-6]
23. van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996; 24: 747-752 [PMID: 8835751 DOI: 10.1016/S0168-8278(96)80272-8]
24. Ewing JF, Raju VS, Maines MD. Induction of heart heme oxygenase-1 (HSP32) by hyperthermia: Possible role in stress-mediated elevation of cyclic 3': 5'-guanosine monophosphate. J Pharmacol Exp Ther 1994; 271: 408-414 [PMID: 7525927]
25. Suematsu M, Ishimura Y. The heme oxygenase-carbon monoxide system: A regulator of hepatobiliary function. Hepatology 2000; 31: 3-6 [PMID: 10613719 DOI: 10.1002/hep.510310102]
26. Raju VS, Imai N, Liang CS. Chamber-specific regulation of heme oxygenase-1 (heat shock protein 32) in right-sided congestive heart failure. J Mol Cell Cardiol 1999; 31: 1581-1589 [PMID: 10423355 DOI: 10.1006/jmcc.1999.0995]
27. Liu H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol 2001; 280: G68-G74 [PMID: 11123199]
28. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N, Sanyal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832 [PMID: 11433348 DOI: 10.1038/89953]
29. Bonz A, Laser M, Küllmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003; 41: 657-664 [PMID: 12658069 DOI: 10.1097/00005344-200304000-00020]
30. Ford WR, Honan SA, White R, Hiley CR. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 2002; 135: 1191-1198 [PMID: 11877326 DOI: 10.1038/sj.bjp.0704565]
31. Ros J, Clària J, To-Figueras J, Planagumà A, Cejudo-Martín P, Fernández-Varo G, Martín-Ruiz R, Arroyo V, Rivera F, Rodés J, Jiménez W. Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122: 85-93 [PMID: 11781284 DOI: 10.1053/gast.2002.30305]
32. Domenicali M, Ros J, Fernández-Varo G, Cejudo-Martín P, Crespo M, Morales-Ruiz M, Briones AM, Campistol JM, Arroyo V, Vila E, Rodés J, Jiménez W. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: Role of cannabinoid and vanilloid receptors. Gut 2005; 54: 522-527 [PMID: 15753538 DOI: 10.1136/gut.2004.051599]
33. Bátkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007; 293: H1689-H1695 [PMID: 17557913 DOI: 10.1152/ajpheart. 00538.2007]
34. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005; 146: 315-323 [PMID: 16025138 DOI: 10.1038/sj.bjp.0706331]
35. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995; 22: 326-332 [PMID: 7608484 DOI: 10.1016/0168-8278 (95)80286-X]
36. Moller S, Henriksen JH. Cardiopulmonary complications in chronic liver disease. World J Gastroenterol 2006; 12: 526-538 [PMID: 16489664]
37. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis. Hepatology 1995; 22: 472-478 [PMID: 7635415]
38. Desai MS, Zainuer S, Kennedy C, Kearney D, Goss J, Karpen SJ. Cardiac structural and functional alterations in infants and children with biliary atresia, listed for liver transplantation. Gastroenterology 2011; 141: 1264-1272, 1272.e1-4 [PMID: 21762660]
39. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Failla M, Grassi G, Giannattasio C, Mancia G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26: 1131-1137 [PMID: 9362352]
40. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, Meregaglia D, Nicolini A. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 56: 869-875 [PMID: 17135305 DOI: 10.1136/gut.2006.102467]
41. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, Masini A, De Castro S, Merli M. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000; 95: 3200-3205 [PMID: 11095342 DOI: 10.1111/j.1572-0241.2000.03252.x]
42. Karasu Z, Mindikoglu AL, Van Thiel DH. Cardiovascular problems in cirrhotic patients. Turk J Gastroenterol 2004; 15: 126-132 [PMID: 15492908]
43. Guazzi M, Polese A, Magrini F, Fiorentini C, Olivari MT. Negative influences of ascites on the cardiac function of cirrhotic patients. Am J Med 1975; 59: 165-170 [PMID: 1155476 DOI: 10.1016/0002-9343(75)90350-2]
44. Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest 1995; 107: 1467-1469 [PMID: 7750353 DOI: 10.1378/chest.107.5.1467]
45. Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-1847 [PMID: 12454841 DOI: 10.1053/gast.2002.37073]
46. Møller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53: 179-190 [PMID: 20462649 DOI: 10.1016/j.jhep.2010.02.023]
47. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995; 22: 370-376 [PMID: 7608490 DOI: 10.1016/0168-8278(95)80292-4]
48. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997; 273: G537-G544 [PMID: 9277435]
49. Jiménez W, Arroyo V. Origins of cardiac dysfunction in cirrhosis. Gut 2003; 52: 1392-1394 [PMID: 12970127 DOI: 10.1136/gut.52.10.1392]
50. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28-34 [PMID: 9425913 DOI: 10.1002/hep.510270106]
51. Aytemir K, Aksöyek S, Ozer N, Gürlek A, Oto A. QT dispersion and autonomic nervous system function in patients with type 1 diabetes. Int J Cardiol 1998; 65: 45-50 [PMID: 9699930 DOI: 10.1016/S0167-5273(98)00091-6]
52. Figueiredo A, Romero-Bermejo F, Perdigoto R, Marcelino P. The end-organ impairment in liver cirrhosis: Appointments for critical care. Crit Care Res Pract 2012; 2012: 539412 [PMID: 22666568 DOI: 10.1155/2012/539412]
53. Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, Vargas HE, Appleton CP. Preoperative dobutamine stress echocardiographic findings and subsequent shortterm adverse cardiac events after orthotopic liver transplantation. Liver Transpl 2008; 14: 886-892 [PMID: 18508373 DOI: 10.1002/lt.21495]
54. Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, Castell J, Margarit C, Esteban R, Guardia J, Genescà J. Cardiac alterations in cirrhosis: Reversibility after liver transplantation. J Hepatol 2005; 42: 68-74 [PMID: 15629509 DOI: 10.1016/j.jhep.2004.09.008]
55. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87: 9-15 [PMID: 11751653 DOI: 10.1136/heart.87.1.9]
56. Navasa M, Feu F, García-Pagán JC, Jiménez W, Llach J, Rimola A, Bosch J, Rodés J. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993; 17: 355-360 [PMID: 8444409 DOI: 10.1002/hep.1840170302]
57. Gadano A, Hadengue A, Widmann JJ, Vachiery F, Moreau R, Yang S, Soupison T, Sogni P, Degott C, Durand F. Hemodynamics after orthotopic liver transplantation: Study of associated factors and long-term effects. Hepatology 1995; 22: 458-465 [PMID: 7635413 DOI: 10.1002/hep.1840220214]
58. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311-1315 [PMID: 10491376 DOI: 10.1161/01.CIR.100.12.1311]
59. McCurley JM, Hanlon SU, Wei SK, Wedam EF, Michalski M, Haigney MC. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004; 44: 1301-1307 [PMID: 15364336 DOI: 10.1016/j.jacc.2004.04.059]
60. Pozzi M, Grassi G, Ratti L, Favini G, Dell'Oro R, Redaelli E, Calchera I, Boari G, Mancia G. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005; 100: 1110-1116 [PMID: 15842586 DOI: 10.1111/j.1572-0241.2005.41060.x]
61. Timoh T, Protano MA, Wagman G, Bloom M, Vittorio TJ. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011; 43: 1649-1653 [PMID: 21693251 DOI: 10.1016/j.transproceed. 2011.01.188]
62. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974; 49: 754-760 [PMID: 4361711 DOI: 10.1161/01.CIR.49.4.755]